Moderna's Run-Up Looks Like Overreaction from Wall Street -- Market Talk
Dow Jones2026/08/20 12:240824 ET - Moderna shares surging 176% on Wednesday may have been an overreaction from Wall Street to the strong results from Moderna and Merck's mRNA-based vaccine for melanoma patients, UBS analysts say. Moderna's valuation jumped to $70 billion; ascribing a modest valuation to the company's Covid-19 revenue, that would imply a $60 billion valuation to the vaccine alone, which would have to translate to $20 billion in annual sales, the analysts say. That could be unrealistically high, they say. The analysts maintain a $150 price target for Moderna after it closed at $174 on Wednesday. Shares slide 10% to $156.30 premarket. (dean.seal@wsj.com)
(END) Dow Jones Newswires
August 20, 2026 08:24 ET (12:24 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro drifts toward the bottom of its range as US rate bets climb
Investors reportedly offering Anthropic allocation shares at premiums of up to 5% ahead of its IPO
According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.
Crypto prices
More
